GSK-1362885(GSK-1362885) - 药物靶点：PYG_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

PYG

作用机制

PYG抑制剂(糖原磷酸化酶抑制剂)

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

非胰岛素依赖型糖尿病22型糖尿病

原研机构

GSK Plc

在研机构-

非在研机构

GSK Plc

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 GSK-1362885 相关的临床试验

NCT01013766 / Completed临床1期

A Randomized, Open-Label Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics ofGSK1362885 in Subjects With Type 2 Diabetes Mellitus

This study is the second administration of GSK1362885 in humans. GSK1362885 is a novel, potent inhibitor of human glycogen phosphorylase (GP) under development for the treatment of type 2 diabetes mellitus (T2DM). This study will investigate the compound's safety, tolerability, pharmacokinetics, and pharmacodynamics in subjects with Type 2 Diabetes Mellitus.

开始日期2009-08-13

申办/合作机构

GSK Plc

NCT00823940 / Completed临床1期

A Single-blind, Randomized, Placebo Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Healthy Normal Subjects.

The study will investigate whether GSK1362885 is safe and well-tolerated when administered to normal healthy subjects. The study will also measure blood levels of the study drug to determine how the body processes the drug (pharmacokinetics) and what effects the drug has on the body (pharmacodynamics).

开始日期2009-01-13

申办/合作机构

GSK Plc

100 项与 GSK-1362885 相关的临床结果

登录后查看更多信息

100 项与 GSK-1362885 相关的转化医学

登录后查看更多信息

100 项与 GSK-1362885 相关的专利（医药）

登录后查看更多信息

100 项与 GSK-1362885 相关的药物交易

登录后查看更多信息